Kynam Capital Management, Lp
- Regulatory AUM
- $2.4B
- Discretionary
- $2.4B
- Clients
- 3
- Avg AUM / client
- $802M
- Accounts
- 3
- Employees
- 3
AUM over time
Reported AUM from Form ADV filings, plotted by filing date · as of Apr 10, 2026
Investments (13F portfolio — 37 positions, $1,621,127,019)
13F period Mar 31, 2026| # | Issuer | Class | Value | Shares | % of 13F | % of AUM |
|---|---|---|---|---|---|---|
| 1 | Syndax Pharmaceuticals Inc | COM | $188,070,402 | 8,050,959 | 11.6% | 7.82% |
| 2 | Celldex Therapeutics Inc New | COM NEW | $185,262,785 | 5,840,567 | 11.4% | 7.7% |
| 3 | Vaxcyte Inc | COM | $169,816,887 | 2,922,335 | 10.5% | 7.06% |
| 4 | Cogent Biosciences Inc | COM | $155,396,870 | 4,037,331 | 9.59% | 6.46% |
| 5 | Vera Therapeutics Inc | CL A | $136,710,552 | 3,398,224 | 8.43% | 5.68% |
| 6 | Beam Therapeutics Inc | COM | $87,746,469 | 3,682,185 | 5.41% | 3.65% |
| 7 | Travere Therapeutics Inc | COM | $72,014,604 | 2,423,918 | 4.44% | 2.99% |
| 8 | Cytomx Therapeutics Inc. | COM | $70,561,537 | 15,013,093 | 4.35% | 2.93% |
| 9 | Biocryst Pharmaceuticals Inc | COM | $54,081,168 | 5,680,795 | 3.34% | 2.25% |
| 10 | Viridian Therapeutics Inc | COM | $45,802,713 | 2,341,652 | 2.83% | 1.9% |
| 11 | Cullinan Therapeutics Inc | COM | $44,251,816 | 3,114,132 | 2.73% | 1.84% |
| 12 | Urogen Pharma Ltd | COM | $40,408,126 | 2,247,393 | 2.49% | 1.68% |
| 13 | Kalvista Pharmaceuticals Inc | COM | $36,655,804 | 1,820,954 | 2.26% | 1.52% |
| 14 | Apellis Pharmaceuticals Inc | COM | $33,189,750 | 825,000 | 2.05% | 1.38% |
| 15 | Legend Biotech Corp | SPONSORED ADS | $28,515,177 | 1,576,295 | 1.76% | 1.19% |
| 16 | Mbx Biosciences Inc | COM | $27,903,750 | 934,799 | 1.72% | 1.16% |
| 17 | Immunocore Hldgs Plc | ADS | $26,680,851 | 884,937 | 1.65% | 1.11% |
| 18 | Sutro Biopharma Inc | COM SHS | $21,735,420 | 872,558 | 1.34% | 0.9% |
| 19 | Revolution Medicines Inc | COM | $20,179,375 | 207,500 | 1.24% | 0.84% |
| 20 | Burning Rock Biotech Ltd | SPONSORED ADS | $19,790,507 | 1,227,555 | 1.22% | 0.82% |
| 21 | Soleno Therapeutics Inc | COM | $18,748,800 | 560,000 | 1.16% | 0.78% |
| 22 | Nurix Therapeutics Inc | COM | $18,518,734 | 1,194,757 | 1.14% | 0.77% |
| 23 | Pharvaris N V | COM | $18,091,159 | 640,395 | 1.12% | 0.75% |
| 24 | Evommune Inc | COM SHS | $14,380,153 | 625,496 | 0.89% | 0.6% |
| 25 | Relay Therapeutics Inc | COM | $14,171,377 | 1,424,259 | 0.87% | 0.59% |
Top 25 of 37 positions from the manager's latest Form 13F · source filing (EDGAR) ↗. 13F covers long US-listed positions only. "% of AUM" is share of the firm's total regulatory AUM (Form ADV Item 5.F).
Who they serve
| Client type | Clients | AUM | % of AUM |
|---|---|---|---|
| Pooled investment vehicles (non-investment companies) | 3 | $2.4B | 100.0% |
Private funds (1)
Reported in Form ADV Section 7.B.(1), filing of Jun 2024 · $1.6B combined gross assets
| Fund | Type | Domicile | Gross assets | Owners |
|---|---|---|---|---|
| Kynam Global Healthcare Master Fund, Lp master | Hedge Fund | Cayman Islands | $1.6B | 88 |
People (2)
| Name | Role / title | Credentials | With firm since | Ownership |
|---|---|---|---|---|
| Tang, Yue, "Nmn" | Limited Partner | Oct 2020 (6y) | 75% or more | |
| Keller, Jared, Joseph | Chief Operating Officer, Chief Compliance Officer | Mar 2024 (2y) | Less than 5% |
Entity owners (Schedule A/B)
| Entity | Title / status | Since | Sch. | Ownership |
|---|---|---|---|---|
| Kynam Capital Management Gp, Llc | General Partner | Oct 2020 | A | Less than 5% |
Undisclosed: 0% – 25% of the firm is not attributable from the filed Schedule A bands.
Roster from the IAPD representatives feed; ownership and acquisition dates from Form ADV Schedule A/B. "Since" is the earliest filed registration or acquisition date.
Private funds (1, $1.6B gross assets)
| Fund | Type | Gross assets | Min. investment | Owners |
|---|---|---|---|---|
| Kynam Global Healthcare Master Fund, Lp | Hedge Fund | $1.6B | $10.0M | 88 |
From Form ADV Section 7.B private fund reporting.
Documents (1 archived)
| Form | Period | Size | |
|---|---|---|---|
| Form ADV (full filing) | 04/10/2026 | 1.23 MB | View · PDF · Source ↗ |
Archived copies of the firm's regulatory filings, versioned by content hash.
Disciplinary disclosures
No disciplinary events reported on the firm's latest Form ADV filing.
How they charge
- • Percentage of assets under management
- • Performance-based fees
Services
- • Portfolio management for pooled investment vehicles
Custody
Firm reports having custody of client funds or securities (Item 9.A).
No custodian data reported or mined yet.
Source
All data on this page comes from this firm's Form ADV filings, reproduced without modification. Latest filing: Apr 10, 2026.
View current Form ADV (SEC/IAPD) ↗